Next -generation probiotics as potential therapeutic supplement for gastrointestinal infections

Introduction

The experimental evolution of gut microbiota and human wellness has witnessed increased recognition in the past decade. In the human gastrointestinal tract, about 100 million bacteria, viruses, and fungi exist that play a symbiotic relationship with human immunity. Simultaneously, the rising concerns and consequences of antimicrobial and antibiotic resistance are shrinking new antibiotic discoveries and demanding alternative approaches for eradicating infectious diseases. The next-generation probiotics (NGPs) could be a potential answer to this global challenge.

Methods

Recognizing the limitations of traditional probiotics in terms of diversity and scope, the study explored the broader applications of NGPs and their potential to address various gut health issues, dysbiosis, and gastrointestinal disorders. Here, we have strengthened the connections between the gut microbiome and overall health, specifically focusing on Helicobacter pylori (H. pylori) infection and inflammatory bowel disease (IBD). Using a narrative approach, the strengths and weaknesses of currently available therapies and fecal microbiota transplantation (FMT) have been described.

Results and discussion

The outcome of this study reveals the promising potential of NGPs in offering targeted interventions that overcome the limitations of existing approaches. We highlight the perspective of NGPs by addressing the benefits, with their anti-inflammatory properties and ability to enhance gut health. However, we also acknowledge crucial gaps in current knowledge in the field of NGPs’ treatment, particularly the limited clinical evidence for their efficacy etc.